Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades

Gilead Sciences Inc. (NASDAQ:GILD) is one of Goldman Sachs apical healthcare stocks. On March 10, Jefferies initiated sum of Gilead Sciences Inc. (NASDAQ:GILD) with a Buy standing and a $180 terms target. The probe steadfast has touted the company’s earnings-per-share maturation and margin-expansion prospects arsenic portion of its bullish thesis.

kurhan / shutterstock.com

According to the probe firm, the institution is not facing immoderate near-term intelligence spot cliffs oregon important operating leverage. Instead, it is good positioned with its HIV franchise and the prospects for follow-on products. The probe steadfast is besides optimistic astir the company’s prospects with the motorboat of Yetzugo successful pre-exposure prophylaxis.

In addition, Gilead Sciences is making important advancement connected its pipeline development. A signifier 3 RAINIER proceedings for cause povetacicept has already met superior and secondary endpoints successful treating immunoglobulin A nephropathy (IgAN).

Amid the pipeline development, Gilead has besides inked a $7.8 cardinal woody to get humor crab cause developer Arcellx. The woody follows a agelong partnership, signed successful 2022, for the commercialization of medicines to combat aggregate myeloma.

Gilead Sciences, Inc. (NASDAQ:GILD) is simply a US-based biopharmaceutical institution that discovers, develops, and commercializes innovative medicines for life-threatening diseases, peculiarly successful virology, oncology, and inflammation. It is known for its enactment successful antiviral therapies for HIV, Hepatitis B and C, and COVID-19, with a beardown absorption connected expanding its interaction globally, including successful Asia.

While we admit the imaginable of GILD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey connected Google News.